In “Naked Price and Trade Secret Overreach,” 22 Yale Journal of Law & Technology 61 (2020), Professor Robin Feldman and her co-author, Charles Tait Graves, draw critical attention to the ever-broadening assertion of trade secret protection as a device to obscure the price of healthcare goods and services. The article explores the danger of trade… Continue reading →
In trying to promote innovation and competition in pharmaceutical drugs, America has allowed the pharmaceutical industry to increase prices well beyond what other developed countries pay and the market should bear. While a majority of Americans say that prescription drugs have made their lives better in the last ten years, nearly 80% find the price… Continue reading →
Soaring healthcare prices currently threaten the viability of our healthcare system and the overall economy. U.S. healthcare spending, both per capita and as a percentage of GDP, far outpaces spending by any other high-income country, without corresponding increases in quality or access to care. Pharmaceutical drug prices, a component of overall healthcare spending, have dramatically… Continue reading →
